Introduction
Glaucoma is a group of heterogeneous diseases characterized by chronic, degenerative optic neuropathy with resultant loss of visual field (1) . It is the second leading cause of blindness in the world (2) , affecting approximately 2.6% of the population over 40 years of age worldwide (3) . The most important, and the only modifiable, causal risk factor for glaucoma is elevated intraocular pressure (IOP) (1) .
IOP is determined by the balance between the rate of production and rate of removal of the aqueous humor (AH). AH is prod¡¡uced by the ciliary epithelium, sieved through the trabecular meshwork (TM), taken up by the Schlemm's canal (SC), and drained into episcleral (ES) veins via aqueous veins (AVs) (1, 4) . The trabecular outflow pathway accounts for 70%-90% of AH removal in humans. In glaucoma, aqueous outflow resistance increases, resulting in increased IOP and subsequent optic neuropathy (5) . Therefore, current glaucoma treatments are aimed at lowering IOP. Medical and surgical treatments for open-angle glaucoma reduce the short-or medium-term risk for optic nerve damage (6) . However, normalization of IOP and arrest of glaucoma development is often not achieved. Moreover, current medical glaucoma treatment strategies are hindered by patient noncompliance with daily administration of eye drops (7) .
The SC is a unique ring-shaped, endothelium-lined vessel that encircles the cornea (8) . It is the final barrier for the AH before returning to systemic circulation, but its specific contribution to AH outflow resistance is unknown (4) . Interestingly, glaucoma patients have a smaller SC (9) , and agenesis or hypoplasia of the SC has been implicated in primary congenital glaucomas (10) (11) (12) (13) . However, it is still unknown whether the SC is a component of the blood or the lymphatic vascular system (1, 4, 14) .
The SC shares striking structural and functional similarities with lymphatic vessels: it forms a blind-ended tube that does not contain blood, but transports AH and antigen-presenting cells into venous circulation (1, 15, 16) . Furthermore, the SC has a continuous endothelial cell (EC) monolayer that lacks fenestrations, lies on a discontinuous basement membrane, is not enclosed by pericytes or smooth muscle cells, and is subjected to a basal-to-apical direction of flow, like lymphatic capillaries (1, 4, 17, 18) . Moreover, connecting fibrils extending from SC ECs into the surrounding cribriform plexus may be involved in preventing SC collapse (17) , analogously to the anchoring filaments found in lymphatic vessels (4, 19, 20) .
Recent years have seen substantial progress in understanding the molecular regulation of lymphangiogenesis (21) . The genetic programs that determine lymphatic EC (LEC) differentiation and growth, making them distinct from blood vessels, involve a number of newly described signal transduction pathways (22) . LECs differentiate from blood vascular ECs (BECs) in the cardinal vein during E9.5-E10.5, when distinct subpopulations of ECs in the anterior cardinal veins commit to the lymphatic lineage and sprout
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Results

SC ECs display molecular features of lymphatic endothelium.
To investigate whether the SC is a lymphatic vessel, we analyzed the expression of LEC markers in mouse, zebrafish, and human eyes. The SC in mouse eyes was visualized using whole-mount immunofluorescence staining of the anterior segment of the eye. By 4-hydroxytamoxifen (4-OHT) into Sox18-CreER T2 LSL-tdTomato (32) lineage tracing mice at P2-P4, around the time when PROX1 is induced. Analysis at P7 indicated that the Sox18 transcription factor promoter was active at the time of venous EC commitment to the SC lineage (Supplemental Figure 1D ). Similar to lymphatic capillaries, SC ECs were not covered by NG2-positive pericytes or SMA-positive vascular smooth muscle cells (Supplemental Figure  2, A and B) . SC ECs displayed zipper-type EC cell-cell junctions and were ensheathed by a thin layer of collagen IV (Supplemental Figure 2 , C and D), like collecting lymphatic vessels. Whereas VEGFR-2 was expressed in nearly all blood and lymphatic vessels around the limbus, VEGFR-3 expression was restricted to SC ECs and ES lymphatic vessels (Supplemental Figure 3B) .
The SC develops postnatally from transscleral veins. The characterization of SC developmental morphogenesis has previously been limited to serial sections (18) , which provide insufficient information. The development of the lymph sacs has recently been achieve lymphatic-specific, tamoxifen-inducible conditional gene deletion also in SC ECs. In these mice, SC and ES lymphatic vessels were specifically and effectively labeled ( Figure 1N ).
PROX1 expression was also detected in human SC ECs ( Figure 1 , O and P). Furthermore, the zebrafish SC analog could be visualized using whole-mount immunofluorescence staining with 2 independent PROX1 antibodies ( Figure 1Q ), which indicates that the lymphatic identity of the SC is conserved in vertebrate evolution.
Further immunofluorescence analysis revealed strong and specific staining for the secreted chemokine ligand CCL21, but little or no expression of the lymphatic hyaluronan receptor LYVE-1, and no expression of the transmembrane O-glycoprotein podoplanin (PDPN) by SC ECs, which expressed abundant levels of the cell matrix adhesion receptor integrin α9, but mostly low levels of the forkhead box transcription factor FOXC2 (Figure 1 , R-T, and Supplemental Figure 1 , A-C; supplemental material available online with this article; doi:10.1172/JCI75395DS1). We also injected M-O and T, Supplemental Video 5, and Supplemental Figure 4 , Q-T). PROX1 and VEGFR-3 expression levels were maintained in adult mice ( Figure 1 , B and C). VEGFR-2 was detected in the thick sections at all stages of SC development, in the CC, and in the ES vasculature (Supplemental Figure 4) . To further validate the blood vascular origin of SC ECs, we used Prox1-CreER T2 Rosa26 mTmG mice to perform lineage tracing. When 4-OHT was injected at P0, prior to the PROX1 induction in SC ECs at around P2, nearly complete GFP labeling of ES LECs was observed, but no GFP + SC ECs. However, additional injection of 4-OHT at P4, after PROX1 was induced, resulted in the labeling of both ES LECs and SC ECs (Supplemental Figure  5 ). These data indicate that SC ECs do not originate from preexisting lymphatic vasculature.
The lymphangiogenic growth factor VEGF-C is critical for SC development. The close resemblance between SC and lymph sac development (23) led us to hypothesize that the lymphangiogenic growth factor VEGF-C plays a critical role in SC development as well. Vegfc -/-mouse embryos are characterized by failure to form the initial LEC sprouts (23, 24) . However, these mice cannot be studied postnatally due to embryonic lethality. We therefore ana- To assess whether During embryogenesis, VEGF-C is expressed predominantly in regions where the lymphatic vessels develop (24) . In Vegfc +/LacZ mice, in which LacZ encoding β-galactosidase has been inserted into the Vegfc locus, X-gal staining revealed prominent VEGF-C expression adjacent to the SC. However, despite the total lack of ES lymphatic vasculature in the Vegfc +/LacZ heterozygous pups that still expressed VEGF-C, the SC appeared normal at P12 compared with WT littermates (Supplemental Figure 7) .
When SC morphology was assessed at P7 in the transgenic mice expressing soluble VEGFR-3 fusion proteins, K14-VEGFR-3 1-3 -Ig mice were distinguished from their WT littermates and K14-VEGFR-3 4-7 -Ig control mice by their markedly hypoplastic SC, iΔLEC and littermate control Vegfr3 fl/fl mice (n = 3 per group) at P7 after induction of Cre activity. Vegfr3 deletion was confirmed using antibodies against VEGFR-3. (E and F) SC morphology (E) and mean area (F; data pooled from 2 litters) in Vegfr2 iΔLEC and littermate control Vegfr2 fl/fl mice (n = 4 per group) mice at P7. Vegfr2 deletion was confirmed using antibodies against VEGFR-2. Arrowhead indicates residual VEGFR-2. Scale bars: 100 μm (A, C, and E). *P < 0.05; **P < 0.01. jci. Vegfd -/-compared with Vegfc iΔR26 eyes, but this was not statistically significant, although the SC sometimes appeared thinner with the compound deletion ( Figure 3, G and H) .
The lymphangiogenic receptor VEGFR-3 is essential for SC development. VEGFR-3 tyrosine kinase activity is essential for lymphatic vessel growth (21) . VEGFR-3 is activated by VEGF-C and VEGF-D, and VEGFR-3 mutations in both mice and in patients Figure 8) . When VEGFR-2, VEGFR-3, or the combination of VEGFR-2 and VEGFR-3 blocking antibodies were administered daily from P0 to P6, SC hypoplasia was detected most significantly in the anti-VEGFR-2-and anti-VEGFR-2/3-treated mice at P7, whereas blocking VEGFR-3 did not lead to a statistically significant reduction in SC area; furthermore, no additive effects were detected when both VEGFR-3 and VEGFR-2 antibodies were used (Figure 4, A and B) . The discrepancy between the effect of Vegfc deletion and VEGFR-3 blocking antibodies lead us to hypothesize that the antibodies had reduced bioavailability in the SC due to blood-eye barrier development and SC transition to a blind-ended tube. Indeed, our data indicated that between P3 and P4, before induction of VEGFR-3 expression in SC ECs, the SC was no longer perfused by blood (Supplemental Figure 4 , U-X). VEGFR-2 expression was also detected in the earliest stages of SC development (Supplemental Figure 4 , A-T), which suggests that the early stages of SC development involve VEGFR-2 but not VEGFR-3 signaling.
The functional importance of VEGFR-3 and VEGFR-2 in later SC development was examined with lymphatic-specific deletion of Vegfr3 or Vegfr2, starting around P2, when PROX1 is induced. The resulting Vegfr3 iΔLEC and Vegfr2 iΔLEC phenotypes thus reflect receptor functions at later stages of development. Induction of Cre activity in Vegfr3 iΔLEC mice by daily 4-OHT injections from P1 to P5 resulted in a markedly hypoplastic SC with reduced surface area at P7 compared with control littermates, indicative of a critical role of VEGFR-3 in SC development. Vegfr3 iΔLEC mice were characterized by SC lacunae that failed to connect with each other, similar to the K14-VEGFR-3 1-3 -Ig and Vegfr2 iΔLEC mice, and no residual VEGFR-3 staining was detected (Figure 4, C and D) . The SC appeared normal in the 4-OHT-treated Vegfr2 iΔLEC mice (Figure 4 , E and F), although Vegfr2 gene deletion was somewhat incomplete.
VEGF-C overexpression induces directional sprouting, proliferation, and migration of SC ECs in adults. VEGF-C has been shown to of the cornea were filled with PROX1-positive SC ECs connected to the original circular SC. Explaining the corneal involvement, β-galactosidase staining revealed effective transfection of the cornea when the adenoviral reporter vector encoding β-galactosidase (AdLacZ) was used ( Figure 5H ). In striking contrast, AdVEGF treatment entirely obliterated the aqueous outflow system at day 4, and by day 14, only a sheet of ECs surrounding the limbus could be detected ( Figure 5A ). Furthermore, treatment with AdVEGF was associated with a marked increase in IOP, resembling neovascular glaucoma (40) . On the other hand, AdVEGF-C-treated eyes had normal IOP compared with AdControl-injected and uninjected eyes at day 4 as well as a trend toward lower IOP at day 14, albeit not statistically significant (Figure 2, D and E) .
To study the effects of long-term VEGF-C overexpression, adeno-associated viral vectors (AAVs) encoding VEGF-C, VEGF, or human serum albumin (HSA) were injected into the anterior chamber of NMRI nu/nu mice, and eyes were analyzed 6 weeks after transduction. Surprisingly, AAV-VEGF-C injection resulted in the extension of PROX1-positive SC outpockets toward the sclera ( Figure 5F ), in the opposite direction of that observed in AdVEGF-C-injected eyes. Although ocular puncture and/or AAV administration by itself resulted in decreased IOP, AAV-VEGF-C induced a more significant decrease of IOP compared with AAV-HSA-injected or uninjected eyes ( Figure 5G ). In striking contrast, AAV-VEGF administration in equal viral particle amounts resulted in the obliteration of the eye (data not shown), associated with massive increases in IOP, forcing an early sacrifice after 2 weeks ( Figure 5G ). To explain preferential scleral growth of the SC, mice injected with AAVs encoding enhanced GFP (EGFP) were analyzed. Immunofluorescence and anti-GFP staining revealed preferential AAV expression in limbal cells and in cells on the scleral side of the SC ( Figure 5I) .
A single intraocular injection of recombinant VEGF-C induces SC enlargement associated with a trend of decreasing IOP.
In order to study the potential of VEGF-C in inducing therapeutic growth of the SC for the reduction of IOP, we studied aged NMRI mice to model the aging-associated changes in the eye that may underline glaucoma, and applied recombinant VEGF-C in order to avoid potential detrimental effects of sustained protein production via viral vectors (Supplemental Figure 9 , A-C). First, to provide proof of principle that recombinant VEGF-C (rVEGF-C) induces SC growth, rVEGF-C, rVEGF, or HSA was injected into the anterior chamber on 3 consecutive days. Upon analysis at day 4, rVEGF-Cinduced proliferation and sprouting of SC ECs was observed preferentially toward the sclera, whereas rVEGF obliterated the vascular aqueous outflow system (Supplemental Figure 10) . While rVEGF induced massive corneal angiogenesis, only mild activation of ES blood vessels was observed in rVEGF-C-injected eyes (Supplemental Figure 9D) . To overcome potential corneal neovascularization and to study the effects of rVEGF-C on aqueous outflow, we further lowered the dose to a single injection of 0.264, 3.8, 6.4, or 9.6 μg rVEGF-C. As a control, we used recombinant mouse serum albumin (rMSA) produced and purified by the same method. By whole-mount immunofluorescence, rVEGF-C treatment was observed to induce mild but clear growth of the SC toward the sclera ( Figure 6A) . Macroscopically, all rVEGF-Cinjected eyes appeared normal ( Figure 6B ). Moreover, rVEGF-C induce sprouting, proliferation, migration, and survival of LECs, both in vitro and in vivo in adults (20, 27, 28) . The role of VEGF-C/ VEGFR-3 signaling in SC development led us to hypothesize that VEGF-C could be used for therapeutic manipulation of the SC in order to facilitate AH outflow in the treatment of glaucoma. To provide initial proof of principle, we first analyzed the effects of VEGF-C or VEGF overexpression in the anterior segment of the eye by using viral vectors.
Adenoviral vectors encoding VEGF-C (AdVEGF-C) or VEGF165 (AdVEGF), or an empty control vector (AdControl), were injected into the anterior chamber of NMRI nu/nu mouse eyes. To assess effects on aqueous outflow facility, IOP measurements were performed before injection and before sacrifice. The effects of VEGF-C and VEGF overexpression on SC ECs were studied in whole-mount eyes stained for PECAM-1 and PROX1. To identify proliferating ECs, mice received an injection of BrdU 2 hours prior to sacrifice, and the BrdU incorporated to nuclear DNA was stained. At day 4, marked sprouting and proliferation of SC ECs was detected in VEGF-C-treated eyes ( Figure 5A ). VEGF-C treatment was associated with an increase in SC surface area, and sprouts from the SC extended almost exclusively toward the inner surface of the cornea ( Figure 5, A-C) . Surprisingly, by 2 weeks, large areas However, bilateral congenital glaucoma is rarely seen in Hennekam syndrome, which may be due to SC developmental defects, as the responsible mutant gene product, CCBE1, is involved in VEGF-C cleavage into its active form (41) .
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Prompted by these findings, we conducted experiments in adult mice to show that VEGF-C overexpression in the anterior chamber of the eye results in the sprouting, proliferation, and migration of SC ECs with a trend toward IOP reduction. VEGF, on the other hand, which is upregulated in neovascular glaucoma, obliterated the AH drainage system. To account for this difference, we show that VEGFR-2 was expressed in all vessels around the limbus, whereas VEGFR-3 expression was restricted to SC ECs and ES lymphatic vessels (see Supplemental Figure 13 ). Most strikingly, a single injection of recombinant VEGF-C induced mild SC lymphangiogenesis without inducing corneal neovascularization or other pathologies, showing a trend toward surprisingly sustained IOP decrease. The relatively modest effect on IOP may be related to differences in the amount of backflush from the 4-μl volume injected into the anterior chamber. Additionally, in mice (unlike in humans), about 80% of the AH outflow does not flow through the SC (42) . These results suggest dramatically opposing roles of VEGF and VEGF-C in the regulation of AH outflow.
In conclusion, our findings may open novel therapeutic avenues for the treatment of glaucoma. Regardless of whether SC ECs are lymphatic, the relatively selective expression of VEGFR-3 and other PROX1 downstream genes may be exploited in glaucoma treatment to specifically modulate SC function, with minimal blood vascular and other side effects. Regarding the potential therapeutic use of rVEGF-C in the treatment of glaucoma, further studies in rabbits and primates are warranted, due to species differences in the AH outflow system and ocular anatomy.
Methods
Antibodies. The following primary antibodies were used for immunostaining of mouse tissues: rabbit anti-mouse PROX1 (diluted 1:200; ref. 43) , goat anti-human PROX1 (diluted 1:500; AF2727, R&D Systems), polyclonal goat anti-mouse VEGFR-3 (diluted 1:100; AF743, R&D Systems), goat anti-mouse VEGFR-2 (diluted 1:100; AF644, R&D Systems), unconjugated rat anti-PECAM-1 (diluted 1:500; clone MEC 13.3, 553370, BD Biosciences -Pharmingen), hamster anti-PECAM-1 (diluted 1:500; clone 2H8, MAB1398Z, Chemicon), Cy3-conjugated mouse anti-SMA (clone 1A4, C6189, Sigma-Aldrich), polyclonal rabbit did not induce any corneal neovascularization, and no pathological changes were detected in H&E staining of rVEGF-C-injected eyes at 2 weeks ( Figure 6, C and D) . Although ocular puncture decreased IOP by itself, rVEGF-C resulted in variable, but often sustained, IOP decrease when using several separate protein lots (Figure 7 , A-C, and Supplemental Figure 11) . In meta-analysis of all experiments, the postinjection average IOP of rVEGF-Ctreated eyes was lower (rVEGF-C, 8.153 ± 0.1711 mmHg, n = 84; rMSA, 9.239 ± 0.1341 mmHg, n = 81; difference, 1.086 ± 0.2184; 95% CI, 0.6543 to 1.517; P < 0.0001; Figure 7D ). Despite the variation in the results, the trend toward lowering of the IOP suggested that a single injection of low-dose rVEGF-C could safely induce SC growth and sustained IOP decrease.
Discussion
In the present study, we established the SC as lymphatic-like vessel that displays many, but not all, features of terminally differentiated lymphatic endothelium. We showed expression of PROX1 by SC ECs in humans, zebrafish, and mice, which indicates that the lymphatic-like identity of the SC is conserved in vertebrate evolution. In mice, SC ECs expressed PROX1, VEGFR-3, CCL21, Itga9, and collagen IV and had no surrounding pericytes or vascular smooth muscle cells, similar to lymphatic capillaries. Moreover, SC ECs were FOXC2 -/lo and characterized by zipper-type interendothelial junctions. However, SC ECs were distinguished from lymphatic endothelium by stronger PECAM-1 expression, little or no LYVE-1 expression, and lack of podoplanin expression.
We demonstrated that the development of the SC occurred in a manner similar to, yet distinct from, the development of the lymph sacs (Supplemental Figure 12 and ref. 23) . SC morphogenesis begins when limbal transcleral veins begin to sprout laterally, form strings of ECs mimicking the strings of initial LECs that connect each other, and coalesce into a primordial SC analogous to the primordial thoracic duct. Unlike in the cardinal veins, where PROX1 is induced in a subset of the venous ECs (24), PROX1 was induced in the SC only after the initial formation of a primordial SC. If SC ECs are defined as truly lymphatic, SC development would represent an exception to the concept that all LECs are derived from lymph sacs (22) . This would also be an exception to the concept that all lymphatic vessels drain into systemic circulation via the thoracic duct and the right lymphatic duct.
The VEGF-C/VEGFR-3 pathway is the first critical pathway described for the development of the lymphatic vascular tree. VEGFR-3 is activated by VEGF-C and VEGF-D, both members of VEGF family of growth factors (21) . In developing lymphatic vessels, VEGF-C is required for the migration of PROX1-expressing initial LECs (23, 24) . In Vegfc -/-mice, PROX1-positive cells committed to the lymphatic lineage are initially seen in the common cardinal veins and the superficial venous plexus, but they fail to migrate to form the primordial thoracic duct and the primordial longitudinal lymphatic vessel (collectively the lymph sacs) (23) . In Vegfc +/-mice, lymph sacs are detected, but they display subsequent defects, leading to hypoplastic lymphatics and lymphedema (24) . We showed here that conditional VEGF-C deletion (Vegfc iΔR26 mice) inhibited SC development. However, even in the absence of both VEGF-C and VEGF-D, the SC could develop, although it was markedly hypoplastic. These differences may reflect the fact jci.org Volume 124 Number 9 September 2014 VEGF-C, VEGF165, HSA, and EGFP, were produced and analyzed as described previously (24, 27, (47) (48) (49) . Protein expression and purification. Full-length human VEGF-C (residues 32-419; ref. 41 ) and mouse albumin (residues 25-608) were cloned into the pFastBac1 (Invitrogen) baculovirus expression vector with mellitin signal peptide and a C-terminal hexahistidine tag. Recombinant baculovirus was produced in Spodoptera frugiperda (Sf9) insect cells grown at +26°C in serum-free Insect-Express (Lonza) medium. For protein expression, Trichoplusia ni (Tn5) insect cells were grown in about 250 ml serum-free Insect-Express (Lonza) medium per 1-l shaker flask at +26°C and 110 rpm shaker speed. The cell cultures were infected with the corresponding recombinant baculovirus at high multiplicity, and at 3 days after infection, the supernatant was harvested by centrifugation for 20 minutes at 8,000 g.
The supernatant was supplemented with 10 mM imidazole and 2 mM NiCl 2 and was loaded onto Ni (50) that was mounted to a stand and clamp according to the manufacturer's recommendation. After the mice were anesthetized with intraperitoneally administered ketamine (60 mg/kg; Ketaminol Vet, Intervet International B.V.) and xylazine (6 mg/kg; Rompun Vet, KVP Pharma + Veterinär Produkte GmbH), they were placed on an adjustable-height platform. The position of the mouse and the platform were adjusted so that the apex of the central cornea was normal to and 2-3 mm away from the probe tip. The digital readout of 6 consecutive IOP measurements was obtained from the tonometer in mm Hg. This was repeated 3 times for each eye. The mean of the 3 readouts was used in the analysis. Repeat IOP measurements were performed at the same time of day as the baseline measurements in order to avoid circadian fluctuations in the readings (51) .
Intraocular injection. After baseline IOP measurements, intraocular injection of the indicated preparations was performed with a 30-gauge, 0.5-inch needle (BD Microlance 3; BD Drogheda) attached to a 10-μl Hamilton microliter syringe (Model 701 LT SYR; Hamilton Co.). The needle was inserted into the anterior chamber 1 mm posterior from the limbus and into the 10:30 clock position in order to avoid larger blood vessels. The needle was inserted through the posterior chamber into the pupil, where the protein was injected. For the recombinant proteins, 0.264, 3.8, 6.4, or 9.6 μg protein was injected. For adenoviral vectors, 5.80 × 10 7 pfu was injected. For AAVs, 3.38 × 10 9 viral particles were injected.
Immunostaining, X-gal staining, BrdU staining, and microscopy. For whole-mount staining, the fixed anterior segment of the eye was separated in a coronal plane. The retina and lens were removed. The tissues were permeabilized in 0.3% Triton X-100 in PBS (PBS-TX) and blocked in 5% donkey serum. Primary antibodies were added anti-LYVE-1 (diluted 1:1,000; ref. 24) , goat anti-CCL21 (diluted 1:100; AF457, R&D Systems), VE-cadherin (diluted 1:100; clone 11D4.1, BD Biosciences -Pharmingen), rabbit anti-mouse collagen IV (diluted 1:1,000; LB-1403, Cosmo Bio), rabbit polyclonal anti-GFP (diluted 1:1,000; TP401, Torrey Pines Biolabs), rabbit anti-NG2 (diluted 1:500; AB5320, Millipore), IgG fraction of rabbit polyclonal anti-mouse podo- , or control mice, 2 μl 4-OHT (25 mg/ml dissolved in ethanol) was injected intragastrically using a 10-μl Hamilton syringe. Daily injections were performed from P0 or P1 to P6, and vessels were analyzed at P7. Deletion effi- ; see Supplemental Methods). For genetic lineage tracing, 4-OHT was injected intraperitoneally at P0 or at P0 and P4, and vessels were analyzed at P7. For Sox18-CreER T2 lineage tracing, 4-OHT was injected at P2, P3, and P4, and vessels were analyzed at P7. After sacrificing the mice, tissues were immersed in 4% paraformaldehyde, washed in PBS, and then processed for whole-mount staining. Zebrafish eyes were provided by P. Panula (University of Helsinki). Human samples. Eyes that had been enucleated due to uveal melanoma were found through the registry of the Ophthalmic Pathology Laboratory of Helsinki University Eye Hospital and provided by T. Kivelä (Helsinki University Central Hospital). 2 formalin-fixed, paraffin-embedded eyes without tumor extension to the ciliary body or glaucoma were selected for analysis.
Generation and in vitro analysis of viral vectors. The adenoviral vectors encoding VEGF-C, VEGF165, LacZ, and the empty CMV (provided by S. Ylä-Herttuala, University of Eastern Finland, Kuopio, Finland), and the adeno-associated viral (AAV) constructs encoding jci.org Volume 124 Number 9 September 2014 using Image J software. For statistical analysis, the surface areas from 3-4 quadrants were averaged from one or both eyes. Statistics. Quantitative data were compared between groups by 2-sample (unpaired Student's) 2-tailed t test assuming equal variance, or 1-or 2-way ANOVA followed by Tukey post-hoc test for multiple comparisons. Values are expressed as mean ± SD, except in graphs (mean ± SEM). A P value less than 0.05 was considered significant.
Study approval. All animal experiments were approved by the Committee for Animal Experiments of the District of Southern Finland and conformed to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Informed consent for human material from the pathology archive was not required because tissue had been excised and originally processed as a routine diagnostic procedure.
to the blocking buffer and incubated with the tissue overnight at RT. After washes in PBS-TX, the tissue was incubated with fluorophoreconjugated secondary antibodies in PBS-TX overnight at RT, followed by washing in PBS-TX. After postfixation in 1% PFA, the tissues were washed with PBS, cut into 4 quadrants, and mounted. For thick cryosections, 50-μm eye sections were air-dried, encircled with a pappen, fixed in 4% PFA for 8 minutes, rehydrated in PBS, and blocked with 3% BSA in PBS-TX at RT. After primary antibody incubation at +4°C in 3% BSA in PBS overnight, sections were washed with PBS and incubated for 2-3 hours with the appropriate fluorophore-conjugated secondary antibody conjugates (diluted 1:300) in 3% BSA in PBS. After washes with 0.1% PBS-TX, sections were mounted. All fluorescently labeled samples were mounted with Vectashield mounting medium containing DAPI (H-1200; Vector Laboratories). For visualization of VEGF-C expression in Vegfc +/LacZ reporter mice, tissues were fixed with 0.2% glutaraldehyde and stained by the β-galactosidase substrate X-Gal (Promega). For BrdU stainings, mice were given 100 mg/kg BrdU by intraperitoneal injection 2 hours before sacrifice. For tyramide signal amplification immunohistochemistry of human sections, see Supplemental Methods.
Microscopy. Fluorescently labeled samples were analyzed with a confocal microscope (Zeiss LSM 510 Meta, objectives ×10 with NA 0.45 and oil objectives ×40 with NA 1.3; Zeiss LSM 5 Duo, objectives ×10 with NA 0.45 and oil objective ×40 with NA 1.3, and Zeiss LSM 780, objectives ×10 with NA 0.45, ×20 with NA 0.80, oil objective ×40 with NA 1.3) using multichannel scanning in frame mode, as described previously (37) . The pinhole diameter was set at 1 Airy unit for detection of the Alexa Fluor 488 signal and was adjusted for identical optical slice thickness for the fluorophores emitting at higher wavelengths. Zeiss ZEN 2010 or LSM AIM (release 4.2) software was used for image acquisition. 3D projections were digitally reconstructed from confocal z stacks. 3D volume renderings and videos were generated with Imaris software (Bitplane). Brightfield microscopy was performed with a Leica DM LB microscope (objectives ×10 with NA 0.25 and ×20 with NA 0.4) with an Olympus DP50 color camera. Images were edited using Image J or Adobe Photoshop software.
Morphometric and quantitative vessel analysis. The vascular surface areas of the SC were quantified as PECAM-1-positive area from confocal micrographs acquired of all intact quarters of the anterior segment
